Trial Outcomes & Findings for Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (NCT NCT02486718)

NCT ID: NCT02486718

Last Updated: 2026-01-14

Results Overview

DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.

• Recruitment status: ACTIVE_NOT_RECRUITING
• Study phase: PHASE3
• Target enrollment: 1280 participants
• Primary outcome timeframe: Up to 95 months
• Results posted on: 2026-01-14

Participant Flow

A total of 1280 participants with resectable Stage IB-IIIA non-small cell lung cancer (NSCLC) were enrolled in this study. Participants took part in the study at 227 investigative sites across 22 countries. The study is still ongoing.

The study consists of 2 phases, an enrollment phase in which participants received up to 4 cycles of adjuvant cisplatin-based chemotherapy followed by randomized phase in which eligible participants were randomized to receive atezolizumab or best supportive care (BSC) i.e.no treatment.

Participant milestones

Measure	Best Supportive Care (BSC) Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Enrollment Phase All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.	Atezolizumab Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Enrollment Phase STARTED	0	1280	0
Enrollment Phase Enrolled Safety-evaluable Population	0	1269	0
Enrollment Phase COMPLETED	0	1005	0
Enrollment Phase NOT COMPLETED	0	275	0
Randomized Phase STARTED	498	0	507
Randomized Phase Randomized Safety Population	495	0	495
Randomized Phase COMPLETED	0	0	0
Randomized Phase NOT COMPLETED	498	0	507

Reasons for withdrawal

Measure	Best Supportive Care (BSC) Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Enrollment Phase All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.	Atezolizumab Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Enrollment Phase Death	0	19	0
Enrollment Phase Symptomatic deterioration	0	1	0
Enrollment Phase Withdrawal by Subject	0	86	0
Enrollment Phase Protocol Violation	0	18	0
Enrollment Phase Physician Decision	0	18	0
Enrollment Phase Reason not provided	0	41	0
Enrollment Phase Disease relapse	0	54	0
Enrollment Phase Lost to Follow-up	0	4	0
Enrollment Phase Adverse Event	0	34	0
Randomized Phase Withdrawal by Subject	47	0	44
Randomized Phase Protocol Violation	0	0	2
Randomized Phase Physician Decision	3	0	0
Randomized Phase Lost to Follow-up	11	0	5
Randomized Phase Disease Relapse	0	0	1
Randomized Phase Death	155	0	154
Randomized Phase Ongoing	282	0	301

Baseline Characteristics

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Baseline characteristics by cohort

Measure	Enrollment Phase n=1280 Participants All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.
Age, Continuous	61.4 years STANDARD_DEVIATION 8.7 • n=14 Participants
Sex: Female, Male Female	427 Participants n=14 Participants
Sex: Female, Male Male	853 Participants n=14 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	18 Participants n=14 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1219 Participants n=14 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	43 Participants n=14 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=14 Participants
Race (NIH/OMB) Asian	307 Participants n=14 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	2 Participants n=14 Participants
Race (NIH/OMB) Black or African American	8 Participants n=14 Participants
Race (NIH/OMB) White	935 Participants n=14 Participants
Race (NIH/OMB) More than one race	1 Participants n=14 Participants
Race (NIH/OMB) Unknown or Not Reported	27 Participants n=14 Participants

PRIMARY outcome

Timeframe: Up to 95 months

Population: Randomized ITT population was defined as all randomized participants with resected Stage IB \[tumors ≥ 4 centimetres (cm)\]-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.

Outcome measures

Measure	Best Supportive Care (BSC) n=498 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=507 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population	47.8 months Interval 37.0 to 65.8	65.6 months Interval 52.4 to The upper limit of the 95% confidence interval (CI) was not estimable due to insufficient number of participants with events.

PRIMARY outcome

Timeframe: Up to 95 months

Population: Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage IIIA, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in participants with disease stage II-IIIA. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.

Outcome measures

Measure	Best Supportive Care (BSC) n=440 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=442 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
DFS in All Randomized Stage II-IIIA Population	40.8 months Interval 31.4 to 57.1	57.4 months Interval 42.2 to The upper limit of the 95% CI was not estimable due to insufficient number of participants with events.

PRIMARY outcome

Timeframe: Up to 95 months

Population: PD-L1 subpopulation, defined as ≥1% TC expression by the SP263 immunohistochemistry (IHC) assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.

DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 ≥1% subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.

Outcome measures

Measure	Best Supportive Care (BSC) n=228 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=248 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population	37.3 months Interval 30.1 to 57.8	68.5 months Interval 51.8 to The upper limit of the 95% CI was not estimable due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Up to 20 years

OS was defined as the time from randomization to death from any cause.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Year 3

Population: Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 3. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=498 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=507 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 3 in ITT Population	55.45 percentage of participants Interval 50.95 to 59.95	61.43 percentage of participants Interval 57.09 to 65.77

SECONDARY outcome

Timeframe: Year 3

Population: Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage III, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=440 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=442 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 3 in All Randomized Stage II-IIIA Population	52.64 percentage of participants Interval 47.83 to 57.46	59.30 percentage of participants Interval 54.61 to 63.98

SECONDARY outcome

Timeframe: Year 3

Population: PD-L1 subpopulation, defined as ≥ 1% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 3. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=228 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=248 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 3 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population	52.05 percentage of participants Interval 45.35 to 58.75	62.72 percentage of participants Interval 56.54 to 68.9

SECONDARY outcome

Timeframe: Year 5

Population: Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 5. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=498 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=507 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 5 in ITT Population	46.48 percentage of participants Interval 41.91 to 51.05	51.96 percentage of participants Interval 47.45 to 56.46

SECONDARY outcome

Timeframe: Year 5

Population: Stage II-IIIA population was defined as all randomized participants with extent of disease as either Stage II or Stage III, and is a subset of the ITT population. Randomized ITT population was defined as all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether or not the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in participants with disease stage II-IIIA. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=440 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=442 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population	44.40 percentage of participants Interval 39.57 to 49.24	49.28 percentage of participants Interval 44.47 to 54.1

SECONDARY outcome

Timeframe: Year 5

Population: PD-L1 subpopulation, defined as ≥ 1% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.

DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.

Outcome measures

Measure	Best Supportive Care (BSC) n=228 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=248 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Disease-free Rate at Year 5 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population	42.69 percentage of participants Interval 36.0 to 49.38	53.15 percentage of participants Interval 46.69 to 59.61

SECONDARY outcome

Timeframe: Up to 95 months

Population: PD-L1 subpopulation, defined as ≥50% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.

DFS was defined as the time from randomization to the first recurrence of NSCLC or occurrence of new primary NSCLC as determined by the investigator or death, whichever occurs first. DFS was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. Kaplan-Meier methodology was used to estimate the median DFS for each treatment arm.

Outcome measures

Measure	Best Supportive Care (BSC) n=114 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=115 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
DFS in the PD-L1 (SP263 ≥ 50% TC) Subpopulation Within the Stage II-IIIA Population	41.1 months Interval 29.7 to The upper limit of the 95% CI was not estimable due to insufficient number of participants with events.	NA months The median and the 95% CI was not estimable due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Up to 20 years

An AE is any untoward medical occurrence in a participant when administered a pharmaceutical product regardless of the causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose (Hour 0) on Day 1 of Cycles 2, 3, 4, 8, 16 (Cycle length = 21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)

Population: ADA evaluable population was defined as all randomized participants who received at least one dose of atezolizumab and who have at least one post-baseline ADA result.

The percentage of ATA (Also called anti-drug antibodies (ADA))-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.

Outcome measures

Measure	Best Supportive Care (BSC) Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=487 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab	—	31.2 percentage of participants

SECONDARY outcome

Timeframe: 30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)

Population: PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Measure	Best Supportive Care (BSC) Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=451 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Maximum Plasma Concentration (Cmax) of Atezolizumab	—	367 micrograms/millilitres (μg/ml) Geometric Coefficient of Variation 124

SECONDARY outcome

Timeframe: Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)

Population: PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Number analyzed is the number of participants with data available for analyses at the specified timepoints.

Outcome measures

Measure	Best Supportive Care (BSC) Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=493 Participants Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 1 Day 1	—	367 μg/ml Geometric Coefficient of Variation 123.5
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 2 Day 1	—	87.8 μg/ml Geometric Coefficient of Variation 79.3
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 3 Day 1	—	141 μg/ml Geometric Coefficient of Variation 58.4
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 4 Day 1	—	170 μg/ml Geometric Coefficient of Variation 57.6
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 8 Day 1	—	222 μg/ml Geometric Coefficient of Variation 40.6
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Cycle 16 Day 1	—	221 μg/ml Geometric Coefficient of Variation 87.3
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Treatment Discontinuation Visit	—	148 μg/ml Geometric Coefficient of Variation 221.8
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab Day 120 Post Last Dose of Atezolizumab	—	8.58 μg/ml Geometric Coefficient of Variation 794.8

Adverse Events

Enrollment Phase

Serious events: 259 serious events

Other events: 1153 other events

Deaths: 19 deaths

Best Supportive Care (BSC)

Serious events: 42 serious events

Other events: 227 other events

Deaths: 155 deaths

Atezolizumab

Serious events: 88 serious events

Other events: 358 other events

Deaths: 154 deaths

Serious adverse events

Measure	Enrollment Phase n=1269 participants at risk All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.	Best Supportive Care (BSC) n=495 participants at risk Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=495 participants at risk Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Blood and lymphatic system disorders Anaemia	0.63% 8/1269 • Number of events 8 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Sarcoidosis of lymph node	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Acute coronary syndrome	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Arrhythmia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Atrial fibrillation	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Cardiac arrest	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Cardiac failure acute	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Cardiac tamponade	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Myocardial infarction	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Myocarditis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Pericardial effusion	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Supraventricular tachycardia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Ear and labyrinth disorders Vertigo	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Adrenal insufficiency	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Hypopituitarism	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Secondary adrenocortical insufficiency	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Eye disorders Retinal detachment	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Eye disorders Vitreous haemorrhage	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Abdominal hernia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Abdominal pain	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Diarrhoea	0.39% 5/1269 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Dyspepsia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Food poisoning	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Gastritis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Large intestine polyp	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Chest pain	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Death	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders General physical health deterioration	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Multiple organ dysfunction syndrome	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Oedema peripheral	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Pyrexia	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Bile duct stone	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Cholelithiasis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Cholestasis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Hepatitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Immune system disorders Anaphylactic reaction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Immune system disorders Contrast media reaction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Immune system disorders Hypersensitivity	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Immune system disorders Immune-mediated adverse reaction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Immune system disorders Sarcoidosis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Abscess limb	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Appendicitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Biliary tract infection	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Bronchitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Cellulitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Device related infection	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Encephalitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Enterocolitis infectious	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Influenza	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Laryngitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Meningitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Otitis media chronic	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pleural infection	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pneumonia	1.4% 18/1269 • Number of events 18 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.6% 8/495 • Number of events 9 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pneumonia pneumococcal	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Respiratory tract infection	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Sepsis	0.39% 5/1269 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Septic shock	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Staphylococcal sepsis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Tonsillitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Urinary tract infection	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Viral myocarditis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Comminuted fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Forearm fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Injury	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Prescribed overdose	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Urethral stricture traumatic	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Blood creatinine increased	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Platelet count decreased	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Weight decreased	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Hyponatraemia	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Arthralgia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Back pain	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal squamous cell carcinoma	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intestinal metastasis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Langerhans' cell histiocytosis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of head and neck	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Urinary tract neoplasm	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Axonal neuropathy	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Cerebellar infarction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Cerebral haemorrhage	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Cerebral infarction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Cerebrovascular accident	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Demyelinating polyneuropathy	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Encephalitis autoimmune	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Encephalopathy	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Intracranial haematoma	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Ischaemic stroke	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Loss of consciousness	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Neuropathy peripheral	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Paraesthesia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Syncope	0.39% 5/1269 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Depression	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Dissociative disorder	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Hallucination, visual	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Renal and urinary disorders Acute kidney injury	0.47% 6/1269 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Reproductive system and breast disorders Adnexal torsion	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Alveolitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.61% 3/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.81% 4/495 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	1.7% 22/1269 • Number of events 22 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/1269 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Deep vein thrombosis	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Thrombophlebitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Agranulocytosis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Bone marrow failure	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Febrile bone marrow aplasia	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Febrile neutropenia	3.0% 38/1269 • Number of events 42 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Leukopenia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Myelosuppression	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Neutropenia	1.0% 13/1269 • Number of events 14 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Pancytopenia	0.08% 1/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Thrombocytopenia	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Angina pectoris	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Arteriosclerosis coronary artery	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Coronary artery disease	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Sinus tachycardia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Tachycardia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Cardiac disorders Ventricular arrhythmia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Ear and labyrinth disorders Otolithiasis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Abdominal pain upper	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Colitis	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Constipation	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Gastric ulcer	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Gastrointestinal inflammation	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Ileus paralytic	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Intestinal perforation	0.08% 1/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Large intestinal obstruction	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Nausea	0.95% 12/1269 • Number of events 12 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Pancreatitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Proctitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Varices oesophageal	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Vomiting	0.79% 10/1269 • Number of events 12 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Asthenia	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Device related thrombosis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Fatigue	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Malaise	0.32% 4/1269 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Pain	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Performance status decreased	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Cholecystitis acute	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Hepatobiliary disorders Jaundice	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Bacteraemia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Bacterial abdominal infection	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Bacterial diarrhoea	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Clostridium difficile colitis	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Device related sepsis	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Diarrhoea infectious	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Diverticulitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Infectious pleural effusion	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Intervertebral discitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Lower respiratory tract infection	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Neutropenic sepsis	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Oral candidiasis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Oral infection	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pneumonia staphylococcal	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pulmonary sepsis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Pulmonary tuberculosis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Stitch abscess	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Upper respiratory tract infection	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Vascular device infection	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Injury, poisoning and procedural complications Vascular access complication	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Alanine aminotransferase increased	0.24% 3/1269 • Number of events 4 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Aspartate aminotransferase increased	0.16% 2/1269 • Number of events 4 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Neutrophil count decreased	0.71% 9/1269 • Number of events 10 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations White blood cell count decreased	0.32% 4/1269 • Number of events 4 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Decreased appetite	0.39% 5/1269 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Dehydration	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Hyperglycaemia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Hyperkalaemia	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Hypokalaemia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Neck pain	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Autonomic neuropathy	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Cerebral ischaemia	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Hypotonia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Intercostal neuralgia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Seizure	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Transient ischaemic attack	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Product Issues Device occlusion	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Catatonia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Delirium	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Panic attack	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Renal and urinary disorders Chronic kidney disease	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Renal and urinary disorders Dysuria	0.08% 1/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Renal and urinary disorders Renal failure	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Bronchial fistula	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Bronchitis chronic	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Bronchopleural fistula	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Chylothorax	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.16% 2/1269 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pleurisy	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pneumothorax spontaneous	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pulmonary artery thrombosis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Pulmonary granuloma	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Subcutaneous emphysema	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Embolism	0.32% 4/1269 • Number of events 4 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Granulomatosis with polyangiitis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Peripheral arterial occlusive disease	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Vascular disorders Subclavian vein thrombosis	0.08% 1/1269 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.

Other adverse events

Measure	Enrollment Phase n=1269 participants at risk All participants received up to four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\] based on investigator's choice), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occurred.	Best Supportive Care (BSC) n=495 participants at risk Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.	Atezolizumab n=495 participants at risk Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
Blood and lymphatic system disorders Anaemia	28.1% 357/1269 • Number of events 422 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.1% 30/495 • Number of events 30 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	7.5% 37/495 • Number of events 47 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Hyperthyroidism	0.55% 7/1269 • Number of events 7 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.61% 3/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.7% 33/495 • Number of events 36 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Endocrine disorders Hypothyroidism	0.24% 3/1269 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.61% 3/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.9% 54/495 • Number of events 61 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Diarrhoea	14.3% 181/1269 • Number of events 226 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.8% 9/495 • Number of events 12 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	7.3% 36/495 • Number of events 54 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Nausea	52.0% 660/1269 • Number of events 1032 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.2% 16/495 • Number of events 16 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.3% 31/495 • Number of events 44 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Asthenia	18.4% 234/1269 • Number of events 301 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.8% 14/495 • Number of events 15 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	7.5% 37/495 • Number of events 45 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Fatigue	21.2% 269/1269 • Number of events 309 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.2% 11/495 • Number of events 14 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.7% 33/495 • Number of events 41 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Pyrexia	5.9% 75/1269 • Number of events 86 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.2% 11/495 • Number of events 14 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	12.1% 60/495 • Number of events 67 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Nasopharyngitis	2.0% 25/1269 • Number of events 26 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.1% 50/495 • Number of events 65 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.7% 33/495 • Number of events 44 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Infections and infestations Upper respiratory tract infection	2.1% 27/1269 • Number of events 33 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.4% 12/495 • Number of events 14 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	7.5% 37/495 • Number of events 43 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Alanine aminotransferase increased	4.1% 52/1269 • Number of events 57 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.2% 16/495 • Number of events 17 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.9% 54/495 • Number of events 71 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Aspartate aminotransferase increased	3.4% 43/1269 • Number of events 47 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.2% 16/495 • Number of events 16 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.9% 54/495 • Number of events 67 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Blood creatinine increased	6.7% 85/1269 • Number of events 113 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.0% 15/495 • Number of events 15 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	5.9% 29/495 • Number of events 36 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Musculoskeletal and connective tissue disorders Arthralgia	2.8% 36/1269 • Number of events 41 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	5.3% 26/495 • Number of events 35 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.5% 52/495 • Number of events 65 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Headache	6.1% 77/1269 • Number of events 90 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.0% 20/495 • Number of events 22 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	5.7% 28/495 • Number of events 39 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Cough	7.3% 93/1269 • Number of events 101 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	9.3% 46/495 • Number of events 55 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	13.3% 66/495 • Number of events 84 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Dyspnoea	5.0% 64/1269 • Number of events 64 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.5% 32/495 • Number of events 33 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	6.3% 31/495 • Number of events 35 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Pruritus	1.7% 22/1269 • Number of events 26 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.61% 3/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	10.3% 51/495 • Number of events 55 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Rash	4.3% 54/1269 • Number of events 58 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 7 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	9.7% 48/495 • Number of events 58 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Leukopenia	6.6% 84/1269 • Number of events 128 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 10 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Neutropenia	26.6% 338/1269 • Number of events 568 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.2% 21/495 • Number of events 33 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Blood and lymphatic system disorders Thrombocytopenia	5.3% 67/1269 • Number of events 94 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 9 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.8% 9/495 • Number of events 11 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Ear and labyrinth disorders Tinnitus	5.4% 69/1269 • Number of events 75 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 8 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Constipation	25.0% 317/1269 • Number of events 389 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.8% 9/495 • Number of events 10 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.8% 24/495 • Number of events 27 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Gastrointestinal disorders Vomiting	19.5% 248/1269 • Number of events 361 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.8% 9/495 • Number of events 9 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.0% 20/495 • Number of events 27 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
General disorders Malaise	5.2% 66/1269 • Number of events 94 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.0% 5/495 • Number of events 5 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Neutrophil count decreased	14.7% 187/1269 • Number of events 367 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.61% 3/495 • Number of events 3 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.8% 9/495 • Number of events 10 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations Platelet count decreased	5.8% 73/1269 • Number of events 108 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.0% 10/495 • Number of events 12 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Investigations White blood cell count decreased	8.7% 111/1269 • Number of events 221 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 7 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Metabolism and nutrition disorders Decreased appetite	24.0% 305/1269 • Number of events 421 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.4% 7/495 • Number of events 7 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.6% 23/495 • Number of events 28 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Dizziness	5.5% 70/1269 • Number of events 74 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.0% 15/495 • Number of events 15 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	3.6% 18/495 • Number of events 20 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Nervous system disorders Dysgeusia	7.5% 95/1269 • Number of events 106 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.20% 1/495 • Number of events 1 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.40% 2/495 • Number of events 2 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Psychiatric disorders Insomnia	5.9% 75/1269 • Number of events 80 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	4.2% 21/495 • Number of events 21 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Respiratory, thoracic and mediastinal disorders Hiccups	7.0% 89/1269 • Number of events 142 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	0.00% 0/495 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.
Skin and subcutaneous tissue disorders Alopecia	14.3% 181/1269 • Number of events 183 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	2.0% 10/495 • Number of events 10 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.	1.2% 6/495 • Number of events 6 • Up to 95 months Enrolled safety-evaluable population included patients in enrollment phase \& received at least 1 dose of chemo. Randomized safety-evaluable population included randomized patients who received at least 1 dose of atezo \& randomized patients who were randomized to control arm \& did not receive any dose of atezo but had at least 1 post-baseline safety assessment, regardless of their assigned treatment at randomization. All-cause mortality reported for deaths that occurred during study based on ITT.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800 821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER